Patent · US Expired

Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

US5342774A · kind A · utility

140Cited by

1References

18Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Thierry Boon · Brussels, BE
Pierre van der Bruggen · Brussels, BE
Benoit Van den Eynde · Brussels, BE
Aline Van Pel · Brussels, BE
Etienne De Plaen · Brussels, BE
Christophe Lurquin · Brussels, BE
Patrick Chomez · Brussels, BE
Catia Traversari · Milano, IT

Key dates

Filing date	Dec 12, 1991
Grant date	Aug 30, 1994
Priority date	—
Expiry date	Dec 12, 2011

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K39/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.